Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome

NCT01075425 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT01075425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01075425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
February 28, 2015
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, myelodysplastic syndrome